Industry Leaders Panel Discussion: Addressing High Dose AAV Delivery
Time: 9:30 am
day: Day One
- Have we reached the highest dose for gene therapy yet?
- Exploring dosing strategies: “One and done or Slower and Lower?”
- What impact would a cumulative vector genome delivery approach have on safety and efficacy?
- Moving away from one and done: what does best practice look like for dosing strategies?
- Which role does complement play in the context of high dose gene therapy delivery